A Study of IDP-001 in Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: InduPro Inc.
- Telefonnummer: 617-798-1770
- E-mail: clinicaltrials@induprotx.com
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- START Los Angeles
-
Kontakt:
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Navid Hafez, M.D.
-
-
Florida
-
Sarasota, Florida, Forenede Stater, 34232
- Rekruttering
- Florida Cancer Specialists
-
Kontakt:
- Telefonnummer: 941-377-9993
- E-mail: clinicaltrials@flcancer.com
-
Ledende efterforsker:
- Manish Patel, M.D.
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46250
- Rekruttering
- Community Cancer Center North
-
Kontakt:
- Adam Norris
- Telefonnummer: 317-621-3858
- E-mail: anorris@ecommunity.com
-
Ledende efterforsker:
- Nikhil Shukla, M.D.
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Ledende efterforsker:
- Prantesh Jain, M.D.
-
Kontakt:
- Telefonnummer: 1-800-767-9355
- E-mail: AskRoswell@RoswellPark.org
-
Lake Success, New York, Forenede Stater, 11042
- Rekruttering
- START New York Long Island
-
Kontakt:
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Geraldine O'Sullivan-Coyne, M.D.
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- START Dallas Forth Worth
-
Kontakt:
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Salwan Al-Mutar, M.D.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options
- Satisfy requirements for prior treatments per tumor type as outlined in the protocol
- Measurable disease per RECIST v1.1
- Participant willing to provide tumor biopsies
- Adequate organ function
- Agree to contraception requirements as outlined in the protocol
- Life expectancy greater than 12 weeks
Exclusion Criteria:
- Any clinically significant cardiac disease
- Any clinically significant corneal disorder
- Known, active, and uncontrolled hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV), or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
- Active significant neurologic disorders
- Requires home oxygen
- Active autoimmune disease
- History or active skin disease requiring frequent treatment
- History of major immunologic reaction to prior immunoglobulin G-containing agent
- Clinically significant ascites or liver disease
- Uncontrolled diabetes or diabetic neuropathy
- Active bleeding disorders
- Participation in a concurrent clinical study in the treatment period
- Pregnant or lactating or planning to become pregnant
- Known hypersensitivity to IDP-001 or any of its ingredients
- Unresolved toxicities from previous anticancer therapy
- Has had a seizure prior to Screening
- Prior solid organ transplant or allogeneic stem cell transplant
- Current endocrinopathy
- History of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis
- History or interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids
- Stroke or transient ischemic attack prior to Screening
- Participant has any other condition or illness that, in the opinion of the Investigator, may compromise participant safety, compliance, or interfere with the conduct and evaluation of the current study.
Note: Other inclusion and exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Phase 1 Part 1 Dose Escalation
Participants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.
|
IV infusion
|
|
Eksperimentel: Phase 1 Part 2 Indication Selection
Participants with a single tumor indication will receive IDP-001 as IV infusion
|
IV infusion
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1
Tidsramme: 3 weeks
|
3 weeks
|
|
Phase 1 Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Duration of Response (DOR) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area Under the Concentration Time Curve (AUC) of IDP-001
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Maximum Observed Plasma Concentration (Cmax) of IDP-001
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Number of Participants with Anti-drug Antibodies (ADAs) in Blood
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: ORR per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 1: DOR per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose Discontinuation
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Disease Control Rate (DCR) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Time to Response (TTR) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Progression Free Survival (PFS) per RECIST Version 1.1 as Assessed by Investigator
Tidsramme: Approximately 6 months
|
Approximately 6 months
|
|
Phase 1 Part 2: Overall Survival (OS)
Tidsramme: Approximately 18 months
|
Approximately 18 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Kolorektale neoplasmer
- Intestinale neoplasmer
- Endetarmssygdomme
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Neoplastiske processer
- Esophageale sygdomme
- Karcinom
- Neoplasmer, pladecelle
- Esophageale neoplasmer
- Anus sygdomme
- Rektale neoplasmer
- Patologiske tilstande, tegn og symptomer
- Planocellulært karcinom i hoved og hals
- Esophageal pladecellekarcinom
- Karcinom, pladecelle
- Neoplasma Metastase
- Anus neoplasmer
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IDP-001-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .